Half-year report · Q2
3034.TEDINET S100URNY
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥124.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥88.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥6.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥137.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥117.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥107.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥79.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥64.9bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥52.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥50.3bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥477m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥265m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥32.43 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.8 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥64m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.4bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥622m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥928m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥125.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥124.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥686m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥7.9bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥63m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥173m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥801m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥142m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥88.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥88.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥237m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 543
| Item | Context | Value | Unit |
|---|---|---|---|
| Allowance for doubtful accounts ca | Prior1YearInstant | -2000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -2000000 | JPY |
| Current assets | Prior1YearInstant | 52690000000 | JPY |
| Current assets | CurrentQuarterInstant | 54399000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 6971000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 7577000000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant | 1448000000 | JPY |
| Tools furniture and fixtures net | CurrentQuarterInstant | 1654000000 | JPY |
| Land | Prior1YearInstant | 6925000000 | JPY |
| Land | CurrentQuarterInstant | 6951000000 | JPY |
| Other net ppe | Prior1YearInstant | 936000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 608000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 16281000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 16791000000 | JPY |
| Goodwill | Prior1YearInstant | 32133000000 | JPY |
| Goodwill | CurrentQuarterInstant | 41547000000 | JPY |
| Business right ia | Prior1YearInstant | － | JPY |
| Business right ia | CurrentQuarterInstant | 12950000000 | JPY |
| Software | Prior1YearInstant | 798000000 | JPY |
| Software | CurrentQuarterInstant | 932000000 | JPY |
| Other ia | Prior1YearInstant | 204000000 | JPY |
| Other ia | CurrentQuarterInstant | 233000000 | JPY |
| Intangible assets | Prior1YearInstant | 33136000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 55663000000 | JPY |
| Investment securities | Prior1YearInstant | 132000000 | JPY |
| Investment securities | CurrentQuarterInstant | 148000000 | JPY |
| Stocks of subsidiaries and affiliates | Prior1YearInstant | 7714000000 | JPY |
| Stocks of subsidiaries and affiliates | CurrentQuarterInstant | － | JPY |
| Lease and guarantee deposits | Prior1YearInstant | 4061000000 | JPY |
| Lease and guarantee deposits | CurrentQuarterInstant | 4133000000 | JPY |
| Deferred tax assets | Prior1YearInstant | 2164000000 | JPY |
| Deferred tax assets | CurrentQuarterInstant | 2085000000 | JPY |
| Other ioa | Prior1YearInstant | 1618000000 | JPY |
| Other ioa | CurrentQuarterInstant | 4085000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -21000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -21000000 | JPY |
| Investments and other assets | Prior1YearInstant | 15670000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 10431000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 65089000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 82887000000 | JPY |
| Assets | Prior1YearInstant | 117779000000 | JPY |
| Assets | CurrentQuarterInstant | 137286000000 | JPY |
| Accounts payable trade | Prior1YearInstant | 22098000000 | JPY |
| Accounts payable trade | CurrentQuarterInstant | 27819000000 | JPY |
| Short term loans payable | Prior1YearInstant | － | JPY |
| Short term loans payable | CurrentQuarterInstant | 4000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 8155000000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | 7604000000 | JPY |
| Income taxes payable | Prior1YearInstant | 2197000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 1984000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |